DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects
作者： André J. Scheen
DOI: 10.1080/17425255.2016.1215427
关键词: Pharmacodynamics 、 Metformin 、 Combination therapy 、 Dipeptidyl peptidase-4 、 Pharmacology 、 Type 2 Diabetes Mellitus 、 Medicine 、 Hypoglycemia 、 Fixed-dose combination 、 Type 2 diabetes
摘要: ABSTRACTIntroduction: Type 2 diabetes (T2D) is a complex disease with multiple defects, which generally require combination of several pharmacological approaches to control hyperglycemia. Combining dipeptidyl peptidase-4 inhibitor (DPP-4i) and sodium-glucose cotransporter type (SGT2i) appears be an attractive approach.Area covered: An extensive literature search was performed analyze the pharmacokinetics, pharmacodynamics clinical experience different gliptin-gliflozin combinations.Expert opinion: There strong rationale for combining DPP-4i SGLT2i in patients T2D because two drugs exert complementary glucose-lowering effects. Dual therapy (initial or stepwise approach) more potent than either monotherapy treated diet exercise already metformin. options safe does not induce hypoglycemia. The additional effect marked when g...
core.ac.uk
sci-hub.se 参考文章(65)
Stephan Matthaei, Doina Catrinoiu, Aleksander Celiński, Ella Ekholm, William Cook, Boaz Hirshberg, Hungta Chen, Nayyar Iqbal, Lars Hansen, Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes. Diabetes Care. ,vol. 38, pp. 2018- 2024 ,(2015) , 10.2337/DC15-0811
Robert M. Guthrie, Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus Postgraduate Medicine. ,vol. 127, pp. 463- 479 ,(2015) , 10.1080/00325481.2015.1044756
Anthony H Barnett, Bernard Charbonnel, Robert G Moses, Sanjay Kalra, None, Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus Current Medical Research and Opinion. ,vol. 31, pp. 1919- 1931 ,(2015) , 10.1185/03007995.2015.1081589
V. Woo, Empagliflozin/linagliptin single-tablet combination: first-in-class treatment option. International Journal of Clinical Practice. ,vol. 69, pp. 1427- 1437 ,(2015) , 10.1111/IJCP.12720
Simeon I. Taylor, Jenny E. Blau, Kristina I. Rother, SGLT2 Inhibitors May Predispose to Ketoacidosis The Journal of Clinical Endocrinology and Metabolism. ,vol. 100, pp. 2849- 2852 ,(2015) , 10.1210/JC.2015-1884
Greg Fulcher, DR Matthews, Vlado Perkovic, D De Zeeuw, KW Mahaffey, C Mathieu, V Woo, C Wysham, G Capuano, M Desai, Wayne Shaw, Frank Vercruysse, G Meininger, B Neal, CANVAS trial collaborative group, None, Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes Diabetes, Obesity and Metabolism. ,vol. 18, pp. 82- 91 ,(2016) , 10.1111/DOM.12589
Chantal Mathieu, Aurelian Emil Ranetti, Danshi Li, Ella Ekholm, William Cook, Boaz Hirshberg, Hungta Chen, Lars Hansen, Nayyar Iqbal, Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes Diabetes Care. ,vol. 38, pp. 2009- 2017 ,(2015) , 10.2337/DC15-0779
David W. Boulton, Sreeneeranj Kasichayanula, Chi Fung Anther Keung, Mark E. Arnold, Lisa J. Christopher, Xiaohui Sophia Xu, Frank LaCreta, Simultaneous oral therapeutic and intravenous 14C‐microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin British Journal of Clinical Pharmacology. ,vol. 75, pp. 763- 768 ,(2013) , 10.1111/J.1365-2125.2012.04391.X
Jinsong Geng, Hao Yu, Yiwei Mao, Peng Zhang, Yingyao Chen, Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes. PharmacoEconomics. ,vol. 33, pp. 581- 597 ,(2015) , 10.1007/S40273-015-0266-Y
André J. Scheen, Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus Drugs. ,vol. 75, pp. 33- 59 ,(2015) , 10.1007/S40265-014-0337-Y